{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-290938","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2021-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.906270+00:00","generated_at":"2026-06-28T23:24:20.575366+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Annexon promotes Yednock to CIO, hires Mattheakis as CSO","bullets":["Ted Yednock, formerly CSO since 2013, promoted to Chief Innovation Officer effective immediately.","Larry Mattheakis appointed Chief Scientific Officer; previously SVP at Protagonist Therapeutics.","Yednock remains on executive committee, chairs Scientific Advisory Board; focus on C1q platform expansion.","Mattheakis brings drug discovery experience; company has three clinical-stage candidates in seven trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-290938","json":"https://secwatch.observer/filing/0001193125-21-290938.json","markdown":"https://secwatch.observer/filing/0001193125-21-290938.md","text":"https://secwatch.observer/filing/0001193125-21-290938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312521290938/0001193125-21-290938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312521290938/d225159d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T23:24:20.575366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a6e0f5bff","claim":"Ted Yednock was appointed as Chief Innovation Officer at Annexon, Inc..","evidence_excerpt":"appointed Ted Yednock, Ph.D. as Chief Innovation Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000119312521290938/0001193125-21-290938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Innovation Officer"}],"fact_type":"executive_change"},{"claim_id":"ae64c7a790","claim":"Larry Mattheakis was appointed as Chief Scientific Officer at Annexon, Inc..","evidence_excerpt":"Larry Mattheakis, Ph.D. as Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000119312521290938/0001193125-21-290938-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}